CCL19-producing fibroblastic stromal cells restrain lung carcinoma growth by promoting local antitumor T-cell responses
Lung cancer is the second most common cancer after prostate cancer for men and breast cancer for women in Europe 1 and worldwide. 2 The dominant subtype of lung cancer is non-small cell lung cancer (NSCLC), with its most abundant forms being adenocarcinoma (ADC) and squamous cell carcinoma (SCC). Although genetic mutations resulting in uncontrolled growth of cancer cells are regarded as the main event in the establishment of primary tumors and progression to metastatic disease, 3 only a small proportion of patients with NSCLC demonstrate a known oncogenic mutation that can be targeted pharmacologically. Chemotherapy remains the first line of treatment for patients without known oncogenic mutations, and treatment options are limited. 4, 5 Moreover, only a fraction of patients with NSCLC respond to novel immunotherapies, such as checkpoint blockade. 6 Despite extensive tumor-and patient-specific heterogeneity, studies on the nontransformed compartments of the tumor microenvironment (TME) have revealed that the cellular structures supporting tumor growth could function as universal targets for tumor therapy. 7, 8 Indeed, almost all tumors, including NSCLC, show accumulation of fibroblastic stromal cells (FSCs), which secrete extracellular matrix (ECM) proteins and soluble mediators, all of which influence tumor progression, local angiogenesis, and antitumor immunity. 9, 10 Interestingly, both tumor-supportive and tumor-suppressive fibroblastic cell types can be found in the TME. 9, [11] [12] [13] [14] Thus it is important to identify and potentially target those fibroblast subsets in the TME that could contribute to resolution of the cancer wound.
The TME is a complex and dynamic meshwork of nontransformed cells that critically influence tumor progression and response to treatment. 9, 15 Within the TME, leukocytes and fibroblasts represent dominant cell populations, and the extent and nature of their crosstalk determines disease progression and clinical outcome in patients with NSCLC. 16 Likewise, tumor infiltration by CD3
1 or CD8 1 T cells represents a favorable prognostic factor in patients with colorectal and breast cancer. 17, 18 Furthermore, accumulation of CD8 1 T cells in the peritumoral stroma identifies patients susceptible to checkpoint blockade in metastatic melanoma, 19 although the underlying mechanisms of CD8 T-cell guidance to the TME remain poorly defined. Because the interaction between tumor-infiltrating T cells and tumor-associated stromal cells precipitates chemokine production in the invasive margin of the tumor 20, 21 and increased expression of CCL21, CCL19, and CCR7 in human tumors is associated with better prognosis, 22 it is likely that the CCR7-CCL19/CCL21 axis functions as the main pathway for intratumoral T-cell activation. Indeed, intratumoral application of recombinant CCL19 23 or CCL21 24 augments antitumor immune responses through recruitment of IFN-g-producing T cells. Hence although the association between chemokine production and accumulation of tumor-infiltrating lymphocytes has been delineated, it still remains unclear whether and to what extent particular subsets of intratumoral FSCs affect the activity and maintenance of tumor-reactive T cells.
Recent studies have shown that the presence of smooth muscle actin (SMA)-and fibroblast-activating protein-expressing fibroblasts in NSCLC lesions correlates with disease progression and poor prognosis. 25, 26 However, a study in a different patient cohort revealed that the presence of SMA 1 fibroblasts might not always predict adverse outcomes in patients with NSCLC and that accumulation of fibroblast-activating protein-positive fibroblasts can be associated with prolonged survival, at least in the SCC subgroup. 27 These contradictory results support the notion that different fibroblast populations exist in the TME and suggest that distinct subpopulations might be endowed with tumor-suppressive potential.
To assess whether fibroblasts with immune-stimulating potential exist in patients with NSCLC, we performed gene expression profiling of lung versus tumor FSCs from patients with ADC and those with SCC and found that CCL19 mRNA expression in tumor FSCs correlates with immune cell infiltration and intratumoral accumulation of CD8 1 T cells. Next, we used preclinical murine model systems to delineate the effect of CCL19-expressing FSCs on lung carcinoma growth. Our analysis revealed that CCL19-expressing FSCs form perivascular niches to promote accumulation and antitumor activity of CD8 1 T cells. The functional importance of CCL19-expressing tumor FSCs for control of immune cell recruitment and tumor development was demonstrated through topical ablation of the cells during growth of experimental lung carcinoma.
Our results indicate that a distinct population of immunestimulating FSCs emerges during the growth of immunogenic tumors to foster immune cell activity within the TME.
METHODS

Human subjects
Patients' samples were obtained from the Institute of Pathology at the Kantonsspital St Gallen after obtaining informed consent from the patients. The study has been approved by the local ethics committee within the frame of the St Gallen Lung Biopsy Biobank project (EKSG 11/044/1B). The first sample was acquired on April 5, 2013 , and the last sample was processed on February 9, 2016.
Stromal cell isolation from human lung tissue
Fresh surgical specimens of NSCLC (1.6 6 0.8 g) and healthy autologous (2.3 6 1.0 g) lung tissue were mechanically disaggregated, and single-cell suspensions were generated by using the gentleMACS technique (Miltenyi Biotech, Bergisch Gladbach, Germany). Samples were depleted consecutively of leukocytes and epithelial/tumor cells by using anti-CD45 and anti-EpCAM Microbeads (Miltenyi Biotech) to enrich for stromal cell fractions. Sorted cells were assessed for viability by using Trypan blue exclusion and preserved in RNAprotect Cell Reagent (Qiagen, Venlo, The Netherlands) at 2808C.
Mice
Bacterial artificial chromosome-transgenic C57BL/6N-Tg(Ccl19-Cre) 489Biat (Ccl19-Cre) mice 28 (C;129S4-Rag2tm1.1Flv Il2rgtm1.1Flv/J) mice were obtained from the Institute for Laboratory Animal Sciences at the University of Z€ urich. Ccl19-Cre mice were bred to Rosa26R-iDTR and R26R-EYFP mice to generate heterozygous Ccl19-EYFP/iDTR mice. All mice were maintained in individually ventilated cages and used at the age of 6 to 9 weeks. Experiments were performed in accordance with federal and cantonal guidelines (Tierschutzgesetz) under permission numbers SG02/14, SG09/14, SG07/16, and SG01/16 and after review and approval by the Veterinary Office of the Canton of St Gallen.
Cell lines
The murine lung cancer cell line Lewis lung carcinoma (LLC) was purchased from ATCC (Manassas, Va), and the LLC-gp line expressing H-2D To generate cDNA for microarray analysis, the Ovation Pico WTA System V2 was used, followed by fragmentation and biotinylation using the Encore Biotin Module (both from NuGEN, San Carlos, Calif). Microarrays were run at the Functional Genomics Center Zurich on the GeneChip Human Gene 2.0 ST platform (Affymetrix, Santa Clara, Calif). Before analysis, all cDNA products were quality controlled by using NanoDrop absorbance (Life Technologies), agarose gel electrophoresis, or both.
Microarray gene expression analysis
Gene expression analysis was performed with R and Bioconductor software. 30 Raw gene expression data were normalized by using the robust multiarray average algorithm in the oligo package. 31 Quality control was performed on all samples according to Affymetrix quality control workflow (Affymetrix, Santa Clara, Calif), and identified outlier samples were removed from subsequent analyses. Differential gene expression was determined by using the empiric Bayes-moderated t test with a Benjamini-Hochberg multiple comparison correction implemented in the limma package. Fold change (FC) was calculated as the difference in robust multiarray average-normalized, log 2 -transformed, pairwise group mean gene expression values. Selection thresholds of jFCj values of greater than 2 and an adjusted P value of less than .05 were used to determine differentially expressed genes. A total of 1011 differentially expressed genes were found in any pairwise group comparison between lung fibroblasts and ADC-and SCC-associated fibroblasts. Principal component analysis was performed for the differentially expressed genes to determine sample phenotype segregation for the first 3 principal components. Volcano plots were generated for log 2 FC values and log 10 adjusted P values for each pairwise group comparison. Heat maps were visualized by using log 2 -transformed, row mean-centered, and row-normalized gene expression values with unbiased hierarchical clustering by using Euclidean distances and the Ward minimum variance method. Gene set enrichment analysis 32 was performed for all genes from healthy lung samples compared with tumor samples. Normalized enrichment scores were calculated for 1000 permutations, and nominal P values were calculated by using the empiric phenotype-based permutation test. P values of less than .05 were considered statistically significant.
Cell isolation from murine tumor tissue
Mice were killed at the indicated time points, and tumor tissue was collected. Tumor-infiltrating hematopoietic cells were isolated by using mechanical disruption of the tissue. For isolation of stromal cells, the tissue was cut into small pieces and subjected to enzymatic digestion in RPMI 1640 medium containing 2% FCS, 20 mmol/L HEPES (all from Lonza), 1 mg/mL Collagenase Type P or II (Sigma-Aldrich), and 25 mg/mL DNaseI (AppliChem, Omaha, Neb) in combination with gentleMACS technology-based mechanical disruption (Miltenyi Biotech). After 30 minutes of incubation at 378C, cell suspensions were washed with PBS containing 0.5% FCS and 10 mmol/L EDTA. Hematopoietic and erythroid cells were depleted with MACS anti-CD45 and anti-Ter119 microbeads (Miltenyi Biotec) to enrich the stromal cell fraction.
Cell ablation
For local FSC ablation in tumor-bearing Ccl19-EYFP/iDTR, Ccl19-EYFP, and Cre-negative littermate control mice, diphtheria toxin (DT; 8 ng) was applied intranasally on days 13 and 15 after tumor challenge. Ablation efficiency was assessed by using flow cytometry at days 18 and 23. Lung-draining lymph nodes were inspected for fibroblastic reticular cell (FRC) network integrity by using confocal microscopy on days 18 and 23. For CD8
1 T-cell depletion, 200 mg of a CD8-neutralizing antibody (clone YTS169.4) was administered intraperitoneally on days 23 and 21 before tumor challenge and on days 2, 5, and 8 after tumor inoculation. Target cell depletion was monitored in peripheral blood, reaching more than 99% reduction of CD8 1 T-cell numbers.
Adoptive T-cell transfer
Single-cell suspensions from spleens of TCR-transgenic P14 mice were prepared by using mechanical disruption and subjected to hypotonic red blood cell lysis. Ccl19-EYFP tumor-bearing mice received intravenous adoptive transfer of 7 3 10 6 Ly5. 
Immunohistochemistry and microscopy
Human and murine tissues were fixed overnight at 48C or for 2 hours at room temperature in freshly prepared 4% paraformaldehyde (Merck Millipore, Billerica, Mass) under agitation. Organs were embedded and oriented in 4% low-melting agarose (Invitrogen, Carlsbad, Calif) in PBS and serially sectioned with a vibratome (VT-1200; Leica, Wetzlar, Germany). Thirty-to 70-mm-thick sections were collected and blocked in PBS containing 10% FCS, 1 mg/mL anti-Fcg receptor (BD Biosciences) or anti-human Fc receptor (Miltenyi Biotec), and 0.1% Triton X-100 (Sigma). Tissues were incubated overnight at 48C with the following antibodies: anti-CD31, anti-ICAM-1, anti-VCAM-1, anti-PDPN (all from eBioscience), anti-CD8, anti-Ly5.1 (all from BioLegend), anti-SMA (Sigma), anti-EYFP (Clontech, Mountain View, Calif), anti-human CCL19 (R&D Systems, Minneapolis, Minn), and anti-human CD8 (BioLegend). Unconjugated antibodies were detected with the following secondary antibodies: DyLight 649-conjugated anti-rat IgG, Alexa Fluor 488-conjugated antirabbit IgG, DyLight 549-conjugated anti-Syrian hamster IgG, DyLight 549-conjugated anti-mouse IgG, and DyLight 549-conjugated streptavidin (all purchased from Jackson Immunotools, Baltimore, Md). Nuclei were stained with 49-6-diamidino-2-phenylindole dihydrochloride (Life Technologies), and sections were mounted on glass microscopy slides by using fluorescence mounting medium (Dako, Carpinteria, Calif). Microscopy of immunofluorescent specimens was performed with a confocal microscope (LSM-710; Carl Zeiss, Obserkochen, Germany), and microscopy data were recorded and processed with ZEN 2010 software (Carl Zeiss). Imaris software (versions 7 and 8; Bitplane, Zurich, Switzerland) was used for reconstruction and histomorphometric analysis of confocal zstacks and mosaic tile scans. For immune histochemistry, human tumor specimens were fixed in 4% formalin (Sigma) and paraffin embedded. Serial sections were collected on microscopy slides and consecutively stained with hematoxylin and eosin or antibodies directed to human a-SMA, CD8, or CD3 (Sigma). Color reaction was achieved by using directly labeled antibodies with horseradish peroxidase or according horseradish peroxidase-labeled secondary antibodies. Bright-field microscopy was performed with a Leica DMRA microscope (Leica Microsystems).
Statistics
Statistical analyses were performed with Prism 5.0 software (GraphPad Software, La Jolla, Calif). Data were analyzed with the nonpaired Student t test or 1-way ANOVA (including the Bonferroni multiple comparisons test). A P value of less than .05 was considered significant. Power analysis of the study was performed in R software by using the pwr package. Power of approximately 89% was estimated to detect a 1-log difference in mRNA expression with a 1s SD, expected number of samples of 25 per group, and type I error rate of 0.05 (2-sided).
Data availability
The authors declare that the data supporting the findings of this study are available within this article and its supplementary information files.
RESULTS
FSC heterogeneity in patients with NSCLC
To elucidate the molecular mechanisms by which tumor FSCs elicit diverse protumor and antitumor activities, we determined gene expression profiles of FSCs from patients with NSCLC and FSCs from adjacent unaffected lung tissue (Fig 1, A) . Overall, 28 patients undergoing debulking surgery of lung cancer have been recruited for the study, with 10 having ADC, 12 having SCC, and 6 having nondifferentiated lung carcinoma (see Table E1 in this article's Online Repository at www.jacionline.org for patients' characteristics). Fresh specimens (each up to 1 cm 3 ) from the tumor covering the margin and unaffected lung tissue were processed by using mechanical and enzymatic procedures to obtain single-cell suspensions. Cells were depleted consecutively of CD45 1 leukocytes and EpCAM 1 cells by using magnetic cell sorting (Fig 1, A) , and the purity of the recovered fibroblastic cell fractions was controlled by using flow cytometric analysis (Fig 1, B) . As expected, CD45 2 EpCAM 2 cells had a high purity (routinely 97% to 99%), with the proportion of CD31 1 endothelial cells being consistently less than 1% (Fig 1,  B) . Further flow cytometric analysis revealed that lung tumor FSCs expressed surface molecules, such as CD44, the FRC marker PDPN, CD90, or the adhesion molecule ICAM-1 (CD54), to a varying degree, whereas lung fibroblasts did not show expression of these molecules (Fig 1, C and D) , indicating that the TME of NSCLC harbors different fibroblast populations.
Molecular characterization of FSCs from patients with ADC and those with SCC was performed by using microarray-based global transcriptomic profiling. We found that in total, 1011 genes were differentially expressed when FSCs from the 2 lung cancer subtypes were compared with FSCs from unaffected lung tissue (see Fig E1, A, in this article's Online Repository at www.jacionline.org). The number of differentially expressed genes was similar in both patients with ADC (n 5 744; Fig 2, A) and those with SCC (n 5 798; Fig 2, B) versus lung fibroblasts. The distinct transcriptional profile of tumor fibroblasts was further corroborated by using hierarchical cluster analysis (see Fig E1, B) . Multidimensional principal component analysis of the differentially expressed genes revealed a distinct stromal cell signature of tumor fibroblasts, which clearly separated from lung fibroblasts (Fig 2, C) . Furthermore, ADC-and SCC-associated fibroblast expression profiles were more similar to each other than to their healthy autologous controls, yet they formed distinct clusters indicating differential gene expression between 2 lung cancer subtypes (Fig 2, C, and see Fig E1, A) . Gene set enrichment analysis revealed that tumor FSCs were enriched in functional signatures associated with cancer progression and poor survival, including those specific for metastasis, angiogenesis/hypoxia, epithelial-to-mesenchymal transition, and pluripotency/stemness (Fig 2, D) .
Because fibroblasts can promote tumor growth through formation of a suitable TME with ECM remodeling, 9 we specifically analyzed genes associated with this biological function and used an in silico-predicted ''matrisome'' list of ECM components. 33 We found that tumor fibroblasts concordantly upregulated various ECM-related factors, including collagens, laminins, and matrix metalloproteases, whereas they downregulated other factors, including C-type lectins and some proteoglycans (see Fig E1, C) . Moreover, the tumor fibroblasts showed a consistent pattern of immune shutdown, having downregulated components of the innate immune system, such as complement factors, the IL-1 receptor axis, and Toll-like receptors, as well as certain cytokines, chemokines, growth factors, the activation markers CD44 and CD86, and various MHC class II molecules (Fig 2, E) . Conversely, the angiogenic (Fig 1, C) and CD54, CD90, CD73 and CD105 (Fig 1, D) , as assessed by using flow cytometry (n 5 4-6 human specimens). Data are representative of at least 4 experiments. Values are displayed as means 6 SDs.
J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 4 growth factors FGF11 and VEGFA and 2 chemokines, CCL19 and CCL26, were among a limited number of immune-related genes that showed enriched expression in tumor fibroblasts (Fig 2, E) . Overall, the global expression pattern of fibroblasts from patients with NSCLC is indicative of conversion toward a cancer-associated fibroblast (CAF) phenotype 9 with increased production of ECM components and loss of immune response-promoting functions. However, we considered the consistent upregulation of CCL19 expression, a signature chemokine of FRCs in secondary lymphoid organs, 34, 35 as indicative of the presence of a fraction of immune-stimulating FSCs within the globally immunosuppressive lung cancer microenvironment.
CCL19 expression by tumor FSCs correlates with immune cell infiltration
FSCs of lymph nodes and other secondary lymphoid organs are not only scaffold-building cells but also function at multiple levels by providing critical stimuli for induction and maintenance of immune responses, including regulation of T-cell migration and survival. 28, 36, 37 In particular, CCL19 production demarcates T-cell zone FRCs, which guide the interaction of T cells and DCs for optimal induction of CD8 1 T-cell responses. 35, 38 Moreover, CCL19-expressing FRC-like cells can arise during inflammatory reactions when their activity is required to coordinate local protective CD8 1 T-cell responses in an immune-privileged tissue. 39 RT-PCR analysis of FSC fractions (Fig 2, A) and in lung versus SCC-associated fibroblasts (Fig 2, B) (Fig 2, A and B) or the empiric gene set-based permutation test (Fig 2, D) . *P < .05, **P < .01, and ***P < .001. (open symbols) and corresponding tumor fibroblasts from patients with primary human NSCLC (solid symbols). mRNA expression of CCL19 (Fig 3, B) and CCL26 (Fig 3, C) high SCC, and arrowheads indicate infiltrating CD3 1 cells. Scale bars 5 100 mm (10 mm in inset). Statistical analyses were performed with the Wilcoxon paired test (Fig 3, A-C) or the unpaired Student t test (Fig 3, D) . Data represent individual values per NSCLC subtype and corresponding lung tissue (Fig 3, A-C and E) or indicate means 6 SEMs (n 5 6-12 samples; Fig 3, D) . *P < .05, **P < .01, and ***P < .001. ns, Not significant.
from all patient samples confirmed that CCL19 mRNA expression was increased during the transformation of lung tissue into the TME (Fig 3, A) . Likewise, CCL26 mRNA expression was consistently greater in tumor FSCs compared with lung FSCs (Fig 3, A) , hence corroborating the microarray analysis, which has identified both chemokine genes as being highly expressed in tumor FSCs. Tumor subtype analysis revealed that CCL19 expression was upregulated in all NSCLC subtype-associated fibroblasts (Fig 3, B) , whereas CCL26 mRNA expression was more variable in ADC-and nondifferentiated carcinomaassociated compared with SCC-associated fibroblasts (Fig 3,  C) . Clearly, the tumor environment attracted substantial amounts of immune cells compared with normal lung tissue, with almost 50% of the cells in patients with ADC expressing the hematopoietic cell marker CD45 (Fig 3, D) . Previously, it has been shown that high expression of CCL19 and its receptor CCR7 in bulk tumor tissue correlates with improved overall-and recurrence-free survival of surgicallyresected lung ADC patients. 40 Here we found a positive correlation between CCL19 expression in tumor FSCs from patients with ADC and those with SCC and infiltration with CD45 1 cells (Fig 3, E) . Histologic analysis of serial sections from lung tumors stained for SMA, CD3, and CD8 revealed that T cells accumulated mainly at the tumor margin in tumors showing both low (Fig 3, F) and high (Fig 3, G) CCL19 mRNA expression. The presence of high CCL19 expression correlated with the appearance of prominent SMA-positive stromal strands in the center of the tumor (Fig 3, G, arrows) , increased infiltration of T cells expressing CD3 and CD8 (Fig 3, G, arrow heads) , and more pronounced perivascular cuffing (Fig 3, G, inset) .
Moreover, CCL19 protein could be detected in SMA-positive stromal strands that were populated by CD8 1 T cells (see Fig E2 , A, in this article's Online Repository at www.jacionline.org). CCL19-producing cells were localized mainly around blood vessels (see Fig E2, A, arrowheads) , a pattern that was also found in human lymphoid tissue from palatine tonsils (see Fig E2, B) . Overall, the positive correlation of CCL19 mRNA expression by tumor FSCs and immune cell infiltration suggests that CCL19-expressing fibroblasts might actively foster immune cell recruitment and activity in the TME.
Tumor immunogenicity shapes intratumoral FSC niches
To determine whether and to what extent a particular tumor FSC population affects T-cell infiltration and tumor growth, we resorted to the murine LLC model. We used an LLC line that exhibits enhanced immunogenicity through expression of a viral antigen derived from glycoprotein of the lymphocytic choriomeningitis virus (LLC-gp). 29 In immunocompetent C57BL/6 (B6) mice LLC-gp tumors grew significantly slower compared with the parental LLC line after bilateral subcutaneous inoculation (Fig 4, A) . Injection of the tumor cells into immune-deficient mice lacking T, B, and natural killer cells because of the absence of RAG2 and the common g chain of cytokine receptors (gc, CD132) revealed no significant differences between the growth kinetics of the 2 tumors (Fig 4, B) . Likewise, antibodymediated ablation of CD8 1 T cells in B6 mice reduced differences in growth behavior of the 2 tumor lines (Fig 4, C) , suggesting that immune cells, mainly CD8
1 T cells recognizing the additional antigen in LLC-gp cells, substantially impede tumor development.
To assess whether slow tumor growth coupled with high tumor immunogenicity impinges on activation of immune-stimulating FSCs with the appearance of CCL19-expressing cells, we injected LLC or LLC-gp cells into mice that produce the EYFP reporter in CCL19-expressing cells (Ccl19-EYFP) mice. 28 Confocal microscopy demonstrated a high abundance of CCL19-expressing cells marked by EYFP expression in the immunogenic LLC-gp tumors, whereas the fast-growing LLC-parental tumors were almost completely devoid of this cell population (Fig 4, D) . Highresolution microscopy revealed that EYFP 1 cells frequently ensheathed SMA-expressing blood vessels in LLC-gp tumors (Fig 4, E) . A substantial proportion of the EYFP 1 cells expressed the pericyte marker NG2 (Fig 4, F) and the FRC marker PDPN (Fig 4, G) , suggesting that the microenvironment of immunogenic tumors fosters the appearance of perivascular FRC-like cells. Indeed, flow cytometry-based quantification of EYFP 1 cells at the start of the exponential growth phase of the tumor at day 12 confirmed the significant increase in CCL19-expressing FSCs during growth of LLC-gp tumors (Fig 4, H) , a finding that was corroborated by quantitative RT-PCR analysis of Ccl19 mRNA expression in bulk tumor tissue at day 12 (Fig 4, I) .
Further flow cytometric characterization of CCL19-expressing cells in subcutaneously engrafted LLC-gp tumors revealed that they resemble perivascular FRC-like cells that appear during viral central nervous system infection 39 with expression of several canonical FRC markers, including PDPN, ICAM-1, VCAM-1 (CD106), or platelet-derived growth factor receptor a (CD140a) (Fig 4, J) . Moreover, the increase in numbers of EYFP 1 cells in LLC-gp tumors compared with LLC tumors was accompanied by a shift in immune cell content at day 12 with a significant increase in T-cell content (Fig 4, K and L) .
Taken together, these data indicate that CD8 1 T cells contribute to the control of the immunogenic LLC-gp tumor and suggest (Fig 4, A) , Rag2 2/2 gc 2/2 (Fig 4, B) , and CD8-depleted C57BL/6 (Fig 4, C) (Fig 4, A-C) and the unpaired Student t test (Fig 4, H, I , and L). that CCL19-expressing FSCs govern, at least partially, the immune-stimulating microenvironment in these tumors.
Interaction of CCL19-expressing FSCs and CD8 1 T cells during lung carcinoma growth
The subcutaneous growth of LLC and LLC-gp tumors has facilitated comparative analyses of growth kinetics and the relation of FSC activation and immune cell infiltration. To resolve the connection between FSC activation and improved tumor control, we used a LLC-gp metastatic model and assessed the growth of an orthotopic tumor in Ccl19-EYFP mice. Tumor-free lungs of naive Ccl19-EYFP mice showed strands of EYFP 1 cells around larger bronchial blood vessels (Fig 5, A, arrows) and a few scattered EYFP 1 cells in the lung parenchyma (Fig 5, A , arrowheads in magnification of boxed area). By day 13 after inoculation, cell-dense clusters appeared in the lung parenchyma (Fig 5, B, arrows) , which displayed an altered organization of the CD31 1 vasculature and showed a higher abundance of perivascular EYFP 1 cells (Fig 5, B , arrowheads in magnification of boxed area). Tumor nodules became macroscopically detectable by day 18, with larger nodules bulging out of the parenchyma (Fig 5, C,  arrow) . Although large nodules were almost devoid of EYFP 1 cells (Fig 5, C, arrow) , smaller tumors harbored a dense meshwork of CCL19-expressing FSCs that were located around smaller and larger SMA 1 blood vessels (Fig 5, C , arrowheads in magnification of boxed area). By day 23, we found clusters of EYFP 1 cells also within larger tumor nodules, both at the tumor margin (Fig 5, D , arrows in magnification of boxed area i) and around blood vessels that pinched into the center of the tumor (Fig 5, D , arrowheads in magnification of boxed area ii).
Both the proportion (Fig 5, E) and absolute numbers (see Fig E3, A, in this article's Online Repository at www.jacionline. org) of EYFP 1 cells in the lung tissue increased substantially during the course of tumor growth. Moreover, EYFP 1 cells displayed features of immune activation with upregulation of PDPN, ICAM-1, and VCAM-1 expression (Fig 5, F) , suggesting engagement with immune cells. Indeed, CCL19-expressing cells colocalized with CD8
1 T cells already on day 13 (Fig 5, G,  arrows) and intermingled with the dense mesh of FRC-like cells on day 18 (Fig 5, G, arrowheads) . The interaction of CD8 1 T cells with EYFP 1 cells in large tumor nodules at day 23 was apparent at the tumor margin (Fig 5, G , asterisks in magnification of boxed area i) and in the tumor center (Fig 5, G , asterisks in magnification of boxed area ii), suggesting that these areas demarcate zones of heightened antitumor immune activity.
To validate the conclusion that focal activation of CCL19-expressing FSCs is linked to CD8 1 T cell-mediated protective tumor immunity, we treated LLC-gp lung tumor-bearing Ccl19-EYFP mice on day 13 with DCs pulsed with the immunodominant gp-derived gp33 peptide and adoptively transferred gp33-reactive congenitally marked P14 TCRtransgenic CD8
1 T cells to facilitate tracking of tumor-specific T cells in situ. Antigen-specific therapeutic immunization led to a rapid and significant reduction of tumor nodules (see Fig E3,  B) and precipitated, despite the loss of tumor mass, a minor increase in total numbers of EYFP 1 cells (see Fig E3, C) . Histologically, we found only remnants of LLC-gp tumors by day 23 with small cell-dense areas that were infiltrated by tumor-specific CD8
1 T cells (marked by the congenic marker Ly5.1) and EYFP 1 cells (Fig 5, H) . Under conditions of enhanced antitumor immunity, EYFP 1 FSCs displayed increased PDPN expression (see Fig E3, D) , and more cells were ICAM-1 and VCAM-1 positive (see Fig E3, E) . Hence these analyses suggest that activation of immune-stimulating FSCs, here resolved as increased Ccl19 expression and acquisition of a FRC-like phenotype, favors the establishment of intratumoral niches that can drive protective CD8
1 T cell-mediated tumor immunity.
CCL19-expressing FSCs restrict lung carcinoma growth
To assess to what extent CCL19-expressing tumor FSCs directly affect immune cell infiltration and lung carcinoma growth, we used the Ccl19-EYFP/iDTR mouse model. 35 In this strain CCL19-expressing fibroblasts can be specifically ablated by using application of DT. Mice bearing LLC-gp lung tumors were treated intranasally with DT on days 13 and 15 (Fig 6,  A) , leading to approximately 80% and 70% ablation of CCL19-expressing cells in lungs and tumors on days 18 and 23, respectively (Fig 6, B) . Importantly, this treatment did not affect immune cell compartments and stromal cell infrastructure of lung-draining tracheal lymph nodes (Fig 6, C) . The partial ablation of CCL19-expressing cells in Ccl19-EYFP/iDTR mice resulted in an increase in tumor growth with the appearance of larger nodules compared with DT-treated Ccl19-EYFP mice (Fig 6, D) . Moreover, local ablation of CCL19-expressing FSCs led to a significant increase in tumor coverage (Fig 6, E) and increased tumor weight (Fig 6, F) . Ablation of CCL19-expressing FSCs did not significantly affect the overall content of immune cells in the lungs (Fig 6, G) or infiltration of B cells or myeloid cells (Fig 6, H) .
In contrast, infiltration with both CD8 1 and CD4 1 T cells was reduced substantially under conditions of local cell ablation (Fig 6,  I) . Moreover, we found consistently fewer activated CD8
1 T cells in lungs that partially lacked CCL19-expressing FRC-like cells, indicating that protective antitumor immunity is, to a large extent, mediated by an immune-stimulating fibroblast-CD8
1 T-cell axis. (Fig 5, A) or injected intravenously with 5 3 10 5 LLC-gp cells 13, 18, or 23 days (Fig 5,  B-D) before analysis. Boxed areas indicate regions for right images. Arrows indicate pulmonary vessels ( Fig  5, A) , cell-dense regions harboring EYFP 1 cells (Fig 5, B) , tumor nodules (Fig 5, C) , and EYFP 1 cells (Fig 5, D) at the tumor margin. Arrowheads indicate perivascular EYFP Together, these data indicate that CCL19-producing, immune-stimulating fibroblasts are a critical component of microenvironmental niches in patients with lung cancer and promote protective antitumor immunity.
DISCUSSION
The reverse translational study presented here reveals the intratumoral localization, phenotype, and function of an immune-stimulating FSC population in patients with lung carcinoma. It appears that the chemokine CCL19 serves as a signature molecule for a distinct tumor FSC subset that steers local antitumor T-cell activity. The perivascular microenvironmental niche generated by CCL19-expressing FSCs in murine lung carcinoma promoted accumulation of antitumor CD8 1 T cells and thereby restrained tumor growth.
Tumors are assemblies of different cell types intertwined by complex cell-cell interactions. Novel high-resolution technologies, such as single-cell mass cytometry or singlecell RNA sequencing, have revealed considerable phenotypic and functional heterogeneity of nontransformed cells in the TME that is determined by unique environmental conditions, cellular history, and stochastic processes. [41] [42] [43] For example, genomic instability and deregulation of cellular processes in tumor cells impinge on the cellular heterogeneity in the TME by affecting cellular phenotype and behavior of tumor FSCs. 43 The analysis provided in our study highlights the profound phenotypic changes associated with transformation of lung FSCs into tumor FSCs. Bulk mRNA expression analysis of human lung cancer FSCs performed in this study confirmed the acquisition of mainly tumor-promoting properties, a phenotype commonly referred to as CAFs. 9 Particularly striking differences between FSCs from human lung versus tumor tissue were the changes in the ''matrisome,'' 33 with increased expression of ECM molecules and loss of a broad range of immune system components. Our finding that expression of the chemokines CCL19 and CCL26 was significantly enhanced in FSCs from patients with NSCLC compared with lung FSCs could be due to a general downregulation of immune-stimulating genes in all fibroblasts and selective retention of a limited set of molecules that foster immune reactivity. However, we consider it more likely that distinct subsets of FSCs exist in the TME, with the majority exhibiting the CAF phenotype and a smaller fraction of FSCs that are specialized in recruiting and maintaining immune cells in the tumor.
Indeed, the dichotomy of protumorigenic ''myofibroblastic'' FSCs and antitumorigenic ''inflammatory'' FSCs in patients with pancreatic ductal ADC has been noted recently by Ohlund et al. 11 Inflammatory fibroblasts in patients with pancreatic cancer exhibit a distinct transcriptional profile, display reduced expression of SMA, and secrete inflammatory cytokines, such as IL-6 and IL-11. 11 It is possible that global stromal cell targeting with the aim to incapacitate protumorigenic FSCs can result in decreased immune surveillance and enhanced tumor growth when immune-stimulating FSCs are damaged. 13 Conversely, targeted therapies that foster activation of particular FSC elements through use of agonistic stimulation of the Hedgehog signaling pathway in patients with pancreatic ductal ADC 44 would restrain tumor growth. The distinction of immunestimulating FSCs from protumorigenic FSCs represents a major gap in our knowledge, which has been filled, at least partially, through the identification of immune-stimulating, CCL19-expressing FSCs in the lung cancer environment. Thus development of novel therapeutics should consider affecting the balance between tumor-promoting CAF and tumor-suppressing FSCs that restrict tumor growth and promote immune cell infiltration and activation. 45 The prototype of immune-stimulating FSCs can be found in secondary lymphoid organs, where, for example, FRCs of the T-cell zone regulate T-cell migration and survival by producing constitutive chemokines, such as CCL19 and CCL21, and affect T-cell survival and differentiation through production of IL-7 35 and IL-15. 37 Conversely, CXCL13-producing B-cell zone reticular cells provide essential factors to promote activation and survival of B cells. 46, 47 Interestingly, blocking FRC maturation through targeted ablation of lymphotoxin-b receptor (LTbR) in CCL19-expressing cells results in arrest of FRC development at the stage of myofibroblastic progenitors that do not efficiently support immune responses in lymph nodes. 28 It is possible that LTbR-dependent processes partially affect the activation of perivascular FSCs to acquire an FRClike phenotype and to foster CD8 1 T-cell responses in the TME. Moreover, CCL19 and CXCL13 produced by perivascular FSCs might foster the development of tertiary lymphoid structures (TLSs), which are frequently found in patients with lung cancer. 48 Protective antitumor effects of the FSC-derived chemokines CCL19 and CXCL13 have been demonstrated in patients with experimental NSCLC 23 and colorectal cancer, 49 respectively, further supporting the notion that immune-stimulating FSCs can exert potent antitumorigenic effects in different malignant diseases. The description of CCL19-expressing FSCs in the murine lung cancer model provided here might support the identification of immune-stimulating FSCs in the context of other human malignancies.
Persistent local immune activation in immunogenic tumors can precipitate TLS generation, which recapitulate the organization of secondary lymphoid organs with chemokine-driven compartmentalization of B-and T-cell areas underpinned by immune-stimulating fibroblasts. 50 Overexpression of components of the LTbR pathway that impinge on FRC maturation, as well as production of the FRC-derived chemokines CCL19 and CCL21, are sufficient to induce TLS formation. 51, 52 Importantly, the presence of TLSs in human tumors correlates not only with improved survival in patients with breast cancer, 53 NSCLC, 54 or melanoma 55 but also with increased numbers of tumor-infiltrating immune cells in patients with colorectal cancer 56 and NSCLC. 54, 57 Hence it is tempting to speculate that generation of an immunestimulating TME starts with local activation of perivascular CCL19-expressing fibroblasts, which promote accumulation of T cells at the tumor margin and around blood vessels that pinch into the tumor tissue. Moreover, it is most likely that persistence of those signals and processes that govern the initial generation of immune-stimulating niches by CCL19-expressing FSCs in the TME fosters the eventual development of TLS.
Taken together, the present study broadens substantially the paradigm of the cancer immune environment [58] [59] [60] by pinpointing a critical role for a defined FSC subset in antitumor immunity. We anticipate that further studies on FSCs in the TME will reveal putative therapeutic targets to bias the composition of the tumor stroma by promoting the generation of an immune-stimulating environment.
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